Raymond James & Associates Lowers Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Raymond James & Associates cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating) by 34.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,617 shares of the biopharmaceutical company’s stock after selling 5,524 shares during the period. Raymond James & Associates’ holdings in Alnylam Pharmaceuticals were worth $2,125,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ALNY. Point72 Asset Management L.P. purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at about $48,597,000. Eaton Vance Management lifted its position in shares of Alnylam Pharmaceuticals by 606.7% in the first quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock valued at $50,005,000 after acquiring an additional 262,893 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Alnylam Pharmaceuticals by 3.0% in the second quarter. Price T Rowe Associates Inc. MD now owns 6,997,082 shares of the biopharmaceutical company’s stock valued at $1,020,524,000 after acquiring an additional 202,916 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 1.2% in the first quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock valued at $1,768,291,000 after acquiring an additional 126,373 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Alnylam Pharmaceuticals by 2.7% in the second quarter. State Street Corp now owns 2,988,859 shares of the biopharmaceutical company’s stock valued at $435,925,000 after acquiring an additional 79,369 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ALNY shares. Canaccord Genuity Group started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 18th. They issued a “buy” rating and a $310.00 price objective on the stock. JPMorgan Chase & Co. reduced their target price on Alnylam Pharmaceuticals from $204.00 to $200.00 and set a “neutral” rating on the stock in a report on Monday, October 24th. HC Wainwright reduced their target price on Alnylam Pharmaceuticals from $430.00 to $415.00 and set a “buy” rating on the stock in a report on Wednesday, November 2nd. Barclays reduced their target price on Alnylam Pharmaceuticals from $240.00 to $236.00 and set an “overweight” rating on the stock in a report on Friday, October 28th. Finally, Piper Sandler lifted their target price on Alnylam Pharmaceuticals from $226.00 to $253.00 and gave the stock an “overweight” rating in a report on Friday, December 16th. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $239.95.

Alnylam Pharmaceuticals Trading Up 0.5 %

ALNY opened at $229.65 on Monday. The stock has a market cap of $28.25 billion, a price-to-earnings ratio of -23.51 and a beta of 0.50. The stock’s 50 day moving average price is $226.65 and its 200-day moving average price is $206.28. Alnylam Pharmaceuticals, Inc. has a one year low of $117.58 and a one year high of $242.97. The company has a debt-to-equity ratio of 3.85, a quick ratio of 3.33 and a current ratio of 3.48.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last released its earnings results on Thursday, October 27th. The biopharmaceutical company reported ($3.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($1.46). The business had revenue of $264.31 million for the quarter, compared to the consensus estimate of $291.81 million. Alnylam Pharmaceuticals had a negative net margin of 123.02% and a negative return on equity of 430.74%. The company’s quarterly revenue was up 40.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.72) EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -9.64 EPS for the current year.

Alnylam Pharmaceuticals Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

Further Reading

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.